¾Û»áÏÖ³¡£¡£¡£¡£¡£¨Í¼Ô´Ö÷Àí·½£©
Ñо¿Ò» »ùÓÚÏÂÒ»´ú²âÐò£¨NGS£©¶ÔÖйúÄÍÒÁÂíÌæÄáÍíÆÚ賦µÀ¼äÖÊÁö»¼Õߵļ̷¢KITÍ»±ä¾ÙÐлùÒò×éÆÊÎö ºÏ×÷µ¥Î» Õã½´óѧҽѧԺÁ¥ÊôÉÛÒÝ·òҽԺǮºÆÈ»Ö÷ÈÎҽʦÍÅ¶Ó Ñо¿ÄÚÈÝ Ñо¿»ùÓÚ2121·Ç·²ÓëÕã½´óѧҽѧԺÁ¥ÊôÉÛÒÝ·òÒ½ÔºÅäºÏÑз¢µÄ賦µÀ¼äÖÊÁö£¨GIST£©»ùÒò¼ì²âÊÔ¼ÁºÐ£¬£¬£¬£¬£¬£¬£¬¼ì²âKIT¡¢PDGFRA¡¢KRAS¡¢BRAF¡¢NF1¡¢SDHA¡¢SDHB¡¢SDHCºÍSDHD 9¸ö»ùÒò¡£¡£¡£¡£¡£»£»£»£»£»£»ØÊ×ÐÔÆÊÎöÁË113Ãû¸´·¢×ªÒÆÐÔGIST»¼Õß×éÖ¯µÄ»ùÒòÍ»±äÇéÐΣ¬£¬£¬£¬£¬£¬£¬ÆäÖÐ103ÈË´ÎΪÊÖÊõ±ê±¾£¬£¬£¬£¬£¬£¬£¬10ÈË´ÎΪ´©´Ì±ê±¾¡£¡£¡£¡£¡£ÊÖÊõ±ê±¾ÖÐÒÁÂíÌæÄáδÄÍÒ©µÄ¸´·¢×ªÒƱ걾ÓÐ38È˴Σ¬£¬£¬£¬£¬£¬£¬ÒÁÂíÌæÄáÄÍÒ©µÄ¸´·¢×ªÒƱ걾ÓÐ65È˴Ρ£¡£¡£¡£¡£ Ñо¿Ð§¹û (1) ÒÁÂíÌæÄáÄÍÒ©µÄ»¼ÕßÔ·¢ÐÔ»ùÒòÍ»±ä£ºKITÍâÏÔ×Ó11(76.9%£¬£¬£¬£¬£¬£¬£¬50/65)£¬£¬£¬£¬£¬£¬£¬KITÍâÏÔ×Ó9(20.0%£¬£¬£¬£¬£¬£¬£¬13/65)£¬£¬£¬£¬£¬£¬£¬KITÍâÏÔ×Ó17(1.5%£¬£¬£¬£¬£¬£¬£¬1/65)£¬£¬£¬£¬£¬£¬£¬PDGFRAÍâÏÔ×Ó18(1.5%£¬£¬£¬£¬£¬£¬£¬1/65)¡£¡£¡£¡£¡£ (2) ÒÁÂíÌæÄáÄÍÒ©µÄ»¼ÕßÄÍÒ©Ôµ¹ÊÔÓÉÆÊÎö£ºKITÍâÏÔ×Ó11Í»±ä»¼Õߵļ̷¢ÐÔÍ»±ä±ÈÀý(90.0%)¸ßÓÚÍâÏÔ×Ó9Í»±ä»¼Õß(15.4%£¬£¬£¬£¬£¬£¬£¬2/13)¡£¡£¡£¡£¡£ (3) KITÍâÏÔ×Ó11Í»±äµÄÒÁÂíÌæÄáÄÍÒ©»¼ÕßÖУ¬£¬£¬£¬£¬£¬£¬¼Ì·¢Í»±äÍâÏÔ×ÓÂþÑÜÈçÏÂ: 28%(14/50)ΪKITÍâÏÔ×Ó13£¬£¬£¬£¬£¬£¬£¬4%(2/50)ΪKITÍâÏÔ×Ó14£¬£¬£¬£¬£¬£¬£¬62%(31/50)ΪKITÍâÏÔ×Ó17£¬£¬£¬£¬£¬£¬£¬8%(4/50)ΪKITÍâÏÔ×Ó18£¬£¬£¬£¬£¬£¬£¬1Àý»¼ÕßΪ¶àÍâÏÔ×ÓÍ»±ä£¬£¬£¬£¬£¬£¬£¬ÄÍҩδ¼ì²âµ½Í»±äΪ10%(5/50)¡£¡£¡£¡£¡£ (4) KITÍâÏÔ×Ó9Í»±äµÄÒÁÂíÌæÄáÄÍÒ©»¼ÕßµÄËùÓм̷¢ÐÔÍ»±ä¾ù±¬·¢ÔÚKITÍâÏÔ×Ó17¡£¡£¡£¡£¡£ (5) PDGFRAÍâÏÔ×Ó18µÄÒÁÂíÌæÄáÄÍÒ©»¼Õ߼̷¢ÐÔÍ»±ä±¬·¢ÔÚPDGFRAÍâÏÔ×Ó12¡£¡£¡£¡£¡£ 2121·Ç·²GIST»ùÒò¼ì²âÏîÄ¿ ±¾Ñо¿ËùÓõļì²âÏîÄ¿¿É¼ì²â賦µÀ¼äÖÊÁöÖ¸ÄÏÍÆ¼öµÄ9¸öÖ÷Òª»ùÒò£¨KIT¡¢PDGFRA¡¢BRAF¡¢KRAS¡¢NF1¡¢SDHA¡¢SDHB¡¢SDHC ºÍ SDHD£© £¬£¬£¬£¬£¬£¬£¬²¢ÇÒÄܹ»Í¬Ê±¼ì²âϵͳºÍÅßϵͻ±ä¡£¡£¡£¡£¡£ ΪÁ˽øÒ»²½Ìù½üÁÙ´²ÐèÇ󣬣¬£¬£¬£¬£¬£¬2121·Ç·²ÒÑÓÚÈÕǰ¶ÔGIST»ùÒò¼ì²âÏîÄ¿¾ÙÐÐÁËÉý¼¶£¬£¬£¬£¬£¬£¬£¬ÓÉÔÀ´¼ì²â9¸ö»ùÒòÉý¼¶µ½22¸ö»ùÒò£¬£¬£¬£¬£¬£¬£¬ÖÜÈ«ÁýÕÖ2024 CSCOÖ¸ÄÏÍÆ¼öµÄ»ùÒò£¬£¬£¬£¬£¬£¬£¬ÈçÍ»±äÐÍGIST(KIT¡¢PDGFRA)¡¢Ò°ÉúÐÍGIST£¨Í»±ä°üÀ¨KIT¡¢PDGFRA¡¢SDHA¡¢SDHB¡¢SDHC¡¢SDHD¡¢BRAF¡¢NF1¡¢KRASºÍPIK3CA£¬£¬£¬£¬£¬£¬£¬¼ì²â»ùÒòÖØÅŰüÀ¨FGFR1¡¢NTRK3ºÍBRAF£©£¬£¬£¬£¬£¬£¬£¬²¢ÇÒ¿ÉÒÔͬʱ¼ì²âÅßϵºÍϵͳͻ±ä£¬£¬£¬£¬£¬£¬£¬¿ÉÓÃÓÚÖ×Áö·Ö×Ó·ÖÐÍ¡¢°ÐÏòÒ©ÎïÖÎÁÆ¡¢ÒÅ´«ÐÔÖ×ÁöµÄÕï¶Ï¡£¡£¡£¡£¡£ Ñо¿¶þ Application value of multi-gene mutation detection in the clinical management of pediatric papillary thyroid carcinoma: A preliminary exploration ºÏ×÷µ¥Î» ½ËÕÊ¡ÖÐÎ÷ҽ͎áÒ½ÔºÍõÓñ¹ú½ÌÊÚÍÅ¶Ó Ñо¿ÄÚÈÝ ÎªÁ˶ԶùͯÈéÍ·×´¼××´ÏÙ°©(PTC)µÄ·Ö×Ó±äÒìÊÂÎñÓÐÒ»¸ö½ÏΪÖÜÈ«µÄÃ÷È·ºÍÊìϤ£¬£¬£¬£¬£¬£¬£¬±¾ÏîÑо¿»ùÓÚ2121·Ç·²µÏ¼Ñ°²?Plus¼××´ÏÙ°©116»ùÒò¼ì²âÏîÄ¿£¬£¬£¬£¬£¬£¬£¬ÆÊÎöÁË15Àý¶ùͯPTC»¼ÕßÖеĻùÒò±äÒìÌØÕ÷£¬£¬£¬£¬£¬£¬£¬Í¬Ê±Óë³ÉÈËPTC»¼ÕßÖÐ116¸ö»ùÒòµÄ±äÒìÇéÐξÙÐнÏÁ¿£¬£¬£¬£¬£¬£¬£¬ÆÊÎöÁ½ÕßÖ®¼äµÄ·Ö×Ó±äÒìÌØÕ÷²î±ð¡£¡£¡£¡£¡£ Ñо¿Éè¼Æ Ñо¿Ð§¹û (1) ¶ùͯPTC»¼ÕߵĻùÒòÍ»±äÆ×¸»ºñ¶øÖش󡣡£¡£¡£¡£ (2) BRAF V600EºÍRETÈÚºÏÑôÐÔÂÊΪ73.33%£¬£¬£¬£¬£¬£¬£¬FNAB²»¿ÉÈ·¶¨ÐÔ×ӵĶùͯ¼××´ÏÙ½á½Ú£¬£¬£¬£¬£¬£¬£¬¶à»ùÒòÍŽáÆÊÎö¿ÉÄÜÌá¸ßÕï¶ÏÂÊ£»£»£»£»£»£»ÐèÔÚ¸ü´óµÄÑù±¾Á¿ºÍÁÙ´²ÊÂÇéÖмÌÐøÑé֤̽Ë÷¡£¡£¡£¡£¡£ (3) ½öÔÚ¶ùͯPTCÖÐÍ»±äµÄ»ùÒò¿ÉÄܶԼ¤Ëغϳɡ¢ÉøÍ¸ºÍ×÷ÓûúÖÆÒÔ¼°¼××´ÏÙ¼¤ËØÐźÅͨ·µÄ¹¦Ð§±¬·¢µ¹ÔËÓ°Ï죬£¬£¬£¬£¬£¬£¬´Ó¶øÔö½ø¼²²¡µÄ±¬·¢ºÍÏ£Íû£¬£¬£¬£¬£¬£¬£¬µ«ÈÔÐè½øÒ»²½Ñо¿ÑéÖ¤¡£¡£¡£¡£¡£ (4) ¶ùͯPTCÖ×ÁöÖ±¾¶Ð¡ÓÚ4cm£¨p<0.001£©£¬£¬£¬£¬£¬£¬£¬ÁÜͶºÏ×ªÒÆÊý´óÓÚ5¸ö£¨p<0.001£©¡£¡£¡£¡£¡£ µÏ¼Ñ°²?Plus¼××´ÏÙ°©116»ùÒò¼ì²â µÏ¼Ñ°²?Plus½ÓÄÉDNA+RNA¹²¼ìÊÖÒÕ£¬£¬£¬£¬£¬£¬£¬¼ì²âÓë¼××´ÏÙ°©±¬·¢Éú³¤Ç×½üÏà¹ØµÄ116¸ö»ùÒò£¬£¬£¬£¬£¬£¬£¬ÖÜÈ«ÁýÕÖº£ÄÚÍâ¼××´ÏÙ°©Ïà¹ØÕïÁÆÖ¸Äϼ°×¨¼Ò¹²Ê¶ÍƼöµÄ»ùÒò¡£¡£¡£¡£¡£ÆäÖÐÈںϻùÒò½ÓÄÉRNA-NGS²âÐòÊÖÒÕ£¬£¬£¬£¬£¬£¬£¬¿ÉÒÔ¼ì²â22¸öÈںϻùÒò£¬£¬£¬£¬£¬£¬£¬Áè¼Ý88ÖÖÈÚºÏÐÎʽ£¬£¬£¬£¬£¬£¬£¬ÇÒÄܼì²â䱨µÀµÄÈںϱäÒ죬£¬£¬£¬£¬£¬£¬Ð§¹ûÔ½·¢ÖÜÈ«¡¢×¼È·¡£¡£¡£¡£¡£¸ÃÏîÄ¿¿ÉÓÃÓÚ³ÉÈ˼°¶ùͯ¼××´ÏÙ½á½ÚÁ¼¶ñÐÔ¸¨ÖúÕï¶Ï¡¢¼××´ÏÙ°©»¼ÕßµÄÔ¤ºóÆÀ¹À¼°¸öÌ廯ÖÎÁƾöÒ飻£»£»£»£»£»Í¬Ê±£¬£¬£¬£¬£¬£¬£¬Í¨¹ýÑ¡ÔñϵͳÍŽáÅßϵͻ±ä¼ì²âÏîÄ¿£¬£¬£¬£¬£¬£¬£¬¿ÉÓÃÓÚÒÅ´«ÐÔ¼××´ÏÙ°©µÄÕï¶Ï¡£¡£¡£¡£¡£